3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Genitourinary
1
Conditions
Pancreatic Neoplasms
8
Breast Neoplasms
4
Neoplasm Metastasis
3
Cholangiocarcinoma
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Urologic Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Pancreatic Adenocarcinoma
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
MMR-D/MSI-H Colorectal Cancers
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Anus Neoplasms
1
Interventions
Gemcitabine
95
Cisplatin
72
Capecitabine
39
Oxaliplatin
38
durvalumab
29
Fluorouracil
27
pembrolizumab
26
Leucovorin
23
S 1 (combination)
19
Nivolumab
14
Irinotecan
14
lenvatinib
13
Bevacizumab
13
tremelimumab
10
130-nm albumin-bound paclitaxel
9
apatinib
8
Trastuzumab
7
Injections
7
Immune Checkpoint Inhibitors
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
Paclitaxel
6
Drug Therapy
6
titanium silicide
5
surufatinib
5
irinotecan sucrosofate
5
gemcitabine-oxaliplatin regimen
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
niraparib
×
Gastrointestinal
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled